Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00094562 · ClinicalTrials.gov registry record · Phase 2
A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss
A Phase 2 study of Cancer and Rheumatoid Arthritis, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT00094562: Completed Phase 2 study of Cancer and Rheumatoid Arthritis, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT00094562 is a Phase 2 study of Cancer and Rheumatoid Arthritis that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 25 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00094562, a Phase 2 study of Cancer and Rheumatoid Arthritis, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of fish oil supplements in maintaining weight in people with disease-related weight loss and/or cachexia.
Conditions Studied
Interventions
- DRUG Fish oil supplement
Study Locations (1)
Maryland
- Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2004-06 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
What the finished NCT00094562 record still lists
NCT00094562 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).
The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Fish oil supplement is the first listed.
NCT00094562 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00094562 about?
NCT00094562 is a clinical study titled "A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss". The purpose of this study is to evaluate the safety and effectiveness of fish oil supplements in maintaining weight in people with disease-related weight loss and/or cachexia.
What is the current status of trial NCT00094562?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2004-06. Estimated completion is 2007-09.
What conditions does trial NCT00094562 study?
This clinical trial studies the following conditions: Cancer, Rheumatoid Arthritis, Chronic Obstructive Pulmonary Disease, Chronic Heart Failure, Cancer Cachexia.
What interventions are being tested in trial NCT00094562?
The interventions under investigation include: Fish oil supplement (DRUG).
Who is sponsoring clinical trial NCT00094562?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00094562 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00094562's enrollment target sits among peer trials
25 537th of 615 higher than 71 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia